Among the 220 ER+ breast cancer patients with no adjuvant treatment, those with TLK2-high tumours showed significantly worse disease-specific survival than the rest of the patients (based on log-rank test, P=0.012). This evidence concerns the gene ESR1 and breast carcinoma.